IL-20 Cytokines Are Involved in the Repair of Airway Epithelial Barrier: Implication in Exposure to Cigarette Smoke and in COPD Pathology

Cells. 2023 Oct 16;12(20):2464. doi: 10.3390/cells12202464.

Abstract

Background: Dysregulated inflammation as seen in chronic obstructive pulmonary disease (COPD) is associated with impaired wound healing. IL-20 cytokines are known to be involved in wound healing processes. The purpose of this study was to use ex vivo and in vitro approaches mimicking COPD to evaluate the potential modulatory role of interleukin-20 (IL-20) on the inflammatory and healing responses to epithelial wounding.

Methods: The expression of IL-20 cytokines and their receptors was investigated in lung-derived samples collected from non-COPD and COPD patients, from mice chronically exposed to cigarette smoke and from airway epithelial cells from humans and mice exposed in vitro to cigarette smoke. To investigate the role of IL-20 cytokines in wound healing, experiments were performed using a blocking anti-IL-20Rb antibody.

Results: Of interest, IL-20 cytokines and their receptors were expressed in bronchial mucosa, especially on airway epithelial cells. Their expression correlated with the disease severity. Blocking these cytokines in a COPD context improved the repair processes after a lesion induced by scratching the epithelial layer.

Conclusions: Collectively, this study highlights the implication of IL-20 cytokines in the repair of the airway epithelium and in the pathology of COPD. IL-20 subfamily cytokines might provide therapeutic benefit for patients with COPD to improve epithelial healing.

Keywords: COPD and epithelial repair; IL-20 cytokine family; airway epithelial cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cigarette Smoking* / adverse effects
  • Cytokines / metabolism
  • Humans
  • Interleukins / metabolism
  • Mice
  • Pulmonary Disease, Chronic Obstructive* / pathology
  • Respiratory Mucosa / metabolism

Substances

  • Cytokines
  • interleukin 20
  • Interleukins

Grants and funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. This work was supported by the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Santé et de la Recherche Médicale (INSERM), the University of Lille (Lille, France) and the Region Hauts de France and Fondation de Recherche en Santé Respiratoire (Paris, France). Funders had no role in study design, data collection, data analysis, interpretation or writing of the report.